Pure Global
NCT06382103

Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

Shanghai Zhongshan Hospital·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
ctDNA monitoring
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Shanghai Zhongshan Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Apr 20, 2024
End date
May 20, 2026
Enrollment
120 participants
Primary outcome

Correlation between ctDNA level and recurrence-free survival (RFS),Correlation between specific plasma protein expression level and recurrence-free survival (RFS)

Summary

Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to
 potentially improve prediction of long term prognosis and guide treatment options of patients
 with hepatocellular carcinoma underwent surgical resection.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06382103
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06382103 through Pure Global AI's free database. This phase not specified trial is sponsored by Shanghai Zhongshan Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.